Table 2.
The association between immune cells and disease severity in patients with COVID-19.
| Immune cells | Number of studies | Participants | Mean difference (95% CI) | P | Effects model | Heterogeneity | |
|---|---|---|---|---|---|---|---|
| I2 | Ph | ||||||
| White blood cell | 25 | 4,278 | 0.83 (0.41, 1.25) | <0.001 | REM | 77 | <0.001 |
| Neutrophil | 18 | 2,446 | 1.50 (1.01, 1.98) | <0.001 | REM | 69 | <0.001 |
| Lymhocyte | 27 | 4,480 | −0.36 (−0.43, −0.30) | <0.001 | REM | 73 | <0.001 |
| T cell | 7 | 637 | −332.48 (−496.93, −168.03) | <0.001 | REM | 92 | <0.001 |
| Helper T cell | 7 | 637 | −204.15 (−289.97, −118.33) | <0.001 | REM | 88 | <0.001 |
| Cytotoxic T cell | 7 | 637 | −107.23 (−182.78, −31.68) | <0.001 | REM | 92 | <0.001 |
| Monocyte | 7 | 1,128 | −0.01 (−0.03, 0.01) | 0.28 | FEM | 0 | 0.28 |
CI, confidence intervals; FEM, fixed-effects model; REM, random-effects model; Ph, p-value of Q-test for heterogeneity.